Evaluation of the Thertapeutic and Preventive Efficacy of 2.5 % Moxidectin/10% Imidacloprid (Advocate(R), Bayer Animal Health) in Dogs Naturally Infected or at Risk of Natural Infection by Dirofilaria repens

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F11%3A43870289" target="_blank" >RIV/62157124:16170/11:43870289 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00436-011-2404-6" target="_blank" >http://dx.doi.org/10.1007/s00436-011-2404-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00436-011-2404-6" target="_blank" >10.1007/s00436-011-2404-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of the Thertapeutic and Preventive Efficacy of 2.5 % Moxidectin/10% Imidacloprid (Advocate(R), Bayer Animal Health) in Dogs Naturally Infected or at Risk of Natural Infection by Dirofilaria repens

Popis výsledku v původním jazyce

The objective of this GCP-compliant clinical field study was to evaluate the efficacy of the combination of moxidectin (minimum dose of 2.5 mg/kg body weight) and imidacloprid (minimum dose of 10.0 mg/kg body weight) spot-on (Advocate(R)) as a preventiveand therapeutic treatment of natural infection by Dirofilaria repens in dogs in the Czech Republic. There were two arms of the study, both negatively controlled. 34 animals were randomly allocated to two groups of the treatment arm; 90 negative animalswere randomly allocated to the preventiv arm groups. All enrolled dogs were observed physically and blood was sampled monthly for Dirofilaria repens microfilaria counts for 18 months by modified Knott test and PCR. 34 dogs were enrolled in the treatmentarm of this study (treated: 18, untreated: 16). The reduction of the log-transformed microfilaria counts was significantly higher in the treatment group on day 28 (p = 0.007), 56, 84 and 112 (p { 0.001). All animals treated were negative

Název v anglickém jazyce

Evaluation of the Thertapeutic and Preventive Efficacy of 2.5 % Moxidectin/10% Imidacloprid (Advocate(R), Bayer Animal Health) in Dogs Naturally Infected or at Risk of Natural Infection by Dirofilaria repens

Popis výsledku anglicky

The objective of this GCP-compliant clinical field study was to evaluate the efficacy of the combination of moxidectin (minimum dose of 2.5 mg/kg body weight) and imidacloprid (minimum dose of 10.0 mg/kg body weight) spot-on (Advocate(R)) as a preventiveand therapeutic treatment of natural infection by Dirofilaria repens in dogs in the Czech Republic. There were two arms of the study, both negatively controlled. 34 animals were randomly allocated to two groups of the treatment arm; 90 negative animalswere randomly allocated to the preventiv arm groups. All enrolled dogs were observed physically and blood was sampled monthly for Dirofilaria repens microfilaria counts for 18 months by modified Knott test and PCR. 34 dogs were enrolled in the treatmentarm of this study (treated: 18, untreated: 16). The reduction of the log-transformed microfilaria counts was significantly higher in the treatment group on day 28 (p = 0.007), 56, 84 and 112 (p { 0.001). All animals treated were negative

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

GJ - Choroby a škůdci zvířat, veterinární medicina

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Parasitology Research

ISSN

0932-0113

e-ISSN

—

Svazek periodika

109

Číslo periodika v rámci svazku

—

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

"S77"-86

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—